Top Suppliers:I want be here

No recommended suppliers. I want be here

Hot CAS#:
56-41-7 108-65-6
56-35-9 64-17-5
67-56-1 108-88-3
141-78-6 1310-73-2
13463-67-7 1333-86-4

677010-34-3

677010-34-3 structure
677010-34-3 structure
  • Name: Motavizumab
  • Chemical Name: (5S,8S,11S,14S,17S,20S,23S,26R,29S,32S,35S)-5-Amino-20-[(2S)-2-butanyl]-6,13,16,19,24,31-hexahydroxy-11-[(1R)-1-hydroxyethyl]-35-(2-hydroxy-2-iminoethyl)-23-(3-hydroxy-3-iminopropyl)-8-[4-({hydroxy[(2R,3R)-3-methyl-3,4-dihydro-2H-pyrrol-2-yl]methylene}amino)butyl]-17-isopropyl-14,32-dimethyl-29-[2-(methylsulfanyl)ethyl]-9,10,27,28-tetraoxo-26-(selanylmethyl)-2-thia-7,12,15,18,21,22,25,30,33,34-decaazahexatriaconta-6,12,15,18,24,30-hexaen-36-oic acid
  • CAS Number: 677010-34-3
  • Molecular Formula: C55H95N15O16S2Se
  • Molecular Weight: 1365.524
  • Catalog: Signaling Pathways Anti-infection RSV
  • Create Date: 2018-07-13 19:46:15
  • Modify Date: 2023-01-21 14:57:30
  • Motavizumab (MEDI-524) is an anti-human RSV (respiratory syncytial virus) monoclonal antibody. Motavizumab can be used in respiratory syncytial virus infection in high-risk infants research[1].
Name (5S,8S,11S,14S,17S,20S,23S,26R,29S,32S,35S)-5-Amino-20-[(2S)-2-butanyl]-6,13,16,19,24,31-hexahydroxy-11-[(1R)-1-hydroxyethyl]-35-(2-hydroxy-2-iminoethyl)-23-(3-hydroxy-3-iminopropyl)-8-[4-({hydroxy[(2R,3R)-3-methyl-3,4-dihydro-2H-pyrrol-2-yl]methylene}amino)butyl]-17-isopropyl-14,32-dimethyl-29-[2-(methylsulfanyl)ethyl]-9,10,27,28-tetraoxo-26-(selanylmethyl)-2-thia-7,12,15,18,21,22,25,30,33,34-decaazahexatriaconta-6,12,15,18,24,30-hexaen-36-oic acid
Description Motavizumab (MEDI-524) is an anti-human RSV (respiratory syncytial virus) monoclonal antibody. Motavizumab can be used in respiratory syncytial virus infection in high-risk infants research[1].
Related Catalog
In Vitro Motavizumab shows activity after F protein initiates interaction with the cell membrane and before virus transcription[2]. Motavizumab inhibits F protein-mediated cell-to-cell fusion[2].
In Vivo Motavizumab (intraperitoneal injection; 1.25 mg in 0.1 ml of PBS/per mouse; once) treatment shows reductions on RSV replication and concentrations of cytokine and chemokines in RSV-infected mice[1]. Animal Model: Seven-week-old female, pathogen-free BALB/c mice intranasally inoculated with 106.5 PFU RSV-A2[1] Dosage: 1.25 mg in 0.1 ml of PBS/per mouse Administration: Intraperitoneal injection; 1.25 mg in 0.1 ml of PBS/per mouse; once Result: Resulted in significant reductions of RSV loads compared with untreated controls on days 1 and 5. Showed lower BAL concentrations of IL-1α, IL-12p70, TNF-α and IFN-γ and serum IL-10 and KC compared with RSV-infected untreated mice.
References

[1]. Mejías A, et al. Motavizumab, a neutralizing anti-Respiratory Syncytial Virus (Rsv) monoclonal antibody significantly modifies the local and systemic cytokine responses induced by Rsv in the mouse model. Virol J. 2007 Oct 25;4:109.

[2]. Huang K, et al. Respiratory syncytial virus-neutralizing monoclonal antibodies motavizumab and palivizumab inhibit fusion. J Virol. 2010 Aug;84(16):8132-40.
Boiling Point 1323.5±75.0 °C at 760 mmHg
Molecular Formula C55H95N15O16S2Se
Molecular Weight 1365.524
Flash Point 754.2±37.1 °C
Exact Mass 1365.568726
LogP 4.43
Vapour Pressure 0.0±0.6 mmHg at 25°C

Chemsrc provides CAS#:677010-34-3 MSDS, density, melting point, boiling point, structure, formula, molecular weight, synthetic route, etc.
title: CAS No. 677010-34-3 | Chemsrc address: https://www.chemsrc.com/en/baike/1529876.html

Home | MSDS/SDS Database Search | Journals | Product Classification | Biologically Active Compounds | Selling Leads | About Us | Disclaimer

Copyright © 2024 ChemSrc All Rights Reserved